Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 104 participants.
Also called NCT04892199
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 104 participants
- Sponsor
- Anders Fink-Jensen, MD, DMSci
- Registry
-
NCT04892199
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Denmark
- Registry status
- Unknown status
Technical summary
Registry record NCT04892199. Randomized; triple masking; primary purpose treatment. Start 2021-09-01 (actual); primary completion 2026-03-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Does GLP-1RA Prevent Deterioration of Metabolic State in Prediabetic and Diabetic Patients Treated With Antipsychotic Medication?
- Condition
- Metabolic Disturbance
- Condition
- Schizophrenia
- Condition
- Type 2 Diabetes
- Condition
- Clozapine
- Condition
- GLP-1
- Condition
- Olanzapine
- Intervention (Drug)
- Semaglutide, 1.34 mg/mL
- Intervention (Drug)
- Semaglutide-placebo
- Lead sponsor
- Anders Fink-Jensen, MD, DMSci
Record details
- Record id
cardio:ct-nct04892199- Content hash
49963590f4085425bc6823592793353581e559c466898ec490201500dd68c758